Siscapa Assay Technologies, founded in 2011, specializes in MRM mass spectrometry and bio-research solutions. The company's core mission is to address complex protein measurement challenges in drug development, clinical trials, and diagnostics. By integrating mass spectrometry with specific antibody recognition, Siscapa assays deliver high precision, sensitivity, and specificity, overcoming the limitations of traditional immunoassays and ligand-binding assays (LBAs). Their optimized assay development pipeline ensures reliable and efficient results for their clients.

Notable figures affiliated with Siscapa Assay Technologies include industry experts in mass spectrometry and bio-research. The company has secured investments from leading venture capital firms focused on biotech innovations. Key achievements include the successful application of their technology in various high-stakes clinical trials and drug development projects. Siscapa's impact is evident in its contribution to more accurate and efficient protein measurement, significantly advancing the fields of diagnostics and therapeutic development.